Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: A HORIZONS-AMI substudy

Journal of Thrombosis and Thrombolysis

Volumn 35, Issue 2, 2013, Pages 200-208

  Kikkert, Wouter J ^d   Claessen, Bimmer E ^a,d   Stone, Gregg W ^a,b   Mehran, Roxana ^a,c   Witzenbichler, Bernhard ^f   Brodie, Bruce R ^h   Wöhrle, Jochen ^g   Witkowski, Adam ⁱ   Guagliumi, Giulio ^e   Zmudka, Krzysztof ^j   Henriques, José P S ^d   Tijssen, Jan G P ^d   Sanidas, Elias A ^a,b   Chantziara, Vasiliki ^a,b   Xu, Ke ^a   Dangas, George D ^a,c  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Ospedali Reuniti di Bergamo   (Italy)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h LeBauer CV Research Foundation   (United States)

ⁱ INSTITUTE OF CARDIOLOGY   (Poland)

^j Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

more..

Author keywords

Biomarkers; Drug eluting stents; Major bleeding; Primary percutaneous coronary intervention

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; CYSTATIN C; D DIMER; ENDOTHELIAL CELL SELECTIVE ADHESION MOLECULE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG ELUTING STENT; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84877033773     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0837-0     Document Type: Article

References (39)

1. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71-86
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502. doi: 10.1056/NEJMoa010746
3. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht Jr. H, Zhao F, Chrolavicius S, Copland I, Fox KAA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281):527-533. doi: 10.1016/s0140-6736(01)05701-4
4. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358(21):2218-2230. doi: 10.1056/NEJMoa0708191
5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045-1057. doi: 10.1056/NEJMoa0904327
6. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665):723-731
7. Lindsey JB, Marso SP, Pencina M, Stolker JM, Kennedy KF, Rihal C, Barsness G, Piana RN, Goldberg SL, Cutlip DE, Kleiman NS, Cohen DJ (2009) Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (evaluation of drug-eluting stents and ischemic events) registry. JACC Cardiovasc Interv 2(11):1074-1082. doi: 10.1016/j.jcin.2009.09.002
8. Suh JW, Mehran R, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wohrle J, Dudek D, Weisz G, Stone GW (2011) Impact of in-hospital major bleeding on late clinical outcomes after primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI (Harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 58(17):1750-1756. doi: 10.1016/j.jacc.2011.07.021
9. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KAA, Wallentin L, Peters RJG, Granger CB, Joyner CD, Yusuf S (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30(6):655-661
10. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114(8):774-782
11. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, White K, Goldberg RJ (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24(20):1815-1823
12. Mehran R, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzenbichler B, Guagliumi G, Lansky AJ, Stone GW (2010) A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 55(23):2556-2566
13. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW (2008) The harmonizing outcomes with revascularization and stents in acute myocardial infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J 156(1):44-56. doi: 10.1016/j.ahj.2008.02.008
14. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R (2009) Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360(19):1946-1959. doi: 10.1056/NEJMoa0810116
15. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R (2001) Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 377(9784):2193-2204. doi: 10.1016/s0140-6736(11)60764-2
16. Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wohrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD (2012) Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. J Thromb Thrombolysis. doi: 10.1007/s11239-012-0706-x
17. World Health Organization (1968) Nutritional anaemias. Report of a WHO scientific group. World Health Organization Tech Rep Ser 405:5-37
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41
19. Ishida T, Kundu RK, Yang E, Hirata Ki, Ho YD, Quertermous T (2003) Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo. J Biol Chem 278(36):34598-34604
20. Yokota T, Oritani K, Butz S, Kokame K, Kincade PW, Miyata T, Vestweber D, Kanakura Y (2009) The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. Blood 113(13):2914-2923
21. Wegmann F, Petri BÝ, Khandoga AG, Moser C, Khandoga A, Volkery S, Li H, Nasdala I, Brandau O, Fassler R, Krombach F, Vestweber D (2006) ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability. J Exp Med 203(7):1671-1677
22. Rudd MA, Johnstone MT, Rabbani LE, George D, Ware JA, Loscalzo J (1991) Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin. Circulation 84(6):2568-2573. doi: 10.1161/01.cir.84.6.2568
23. Nasdala I, Wolburg-Buchholz K, Wolburg H, Kuhn A, Ebnet K, Brachtendorf G, Samulowitz U, Kuster B, Engelhardt B, Vestweber D, Butz S (2002) A transmembrane tight junction protein selectively expressed on endothelial cells and platelets. J Biol Chem 277(18):16294-16303
24. O'Connor MN, Salles II, Cvejic A, Watkins NA, Walker A, Garner SF, Jones CI, Macaulay IC, Steward M, Zwaginga JJ, Bray SL, Dudbridge F, de Bono B, Goodall AH, Deckmyn H, Stemple DL, Ouwehand WH (2009) Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood 113(19):4754-4762
25. Stalker TJ, Wu J, Morgans A, Traxler EA, Wang L, Chatterjee MS, Lee D, Quertermous T, Hall RA, Hammer DA, Diamond SL, Brass LF (2009) Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. J Thromb Haemost 7(11):1886-1896
26. Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A (1990) Structure and expression of the human cystatin C gene. Biochem J 268(2):287-294
27. Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38(Suppl 1):S20-S27
28. Shimizu-Tokiwa A, Kobata M, Io H, Kobayashi N, Shou I, Funabiki K, Fukui M, Horikoshi S, Shirato I, Saito K, Tomino Y (2002) Serum cystatin c is a more sensitive marker of glomerular function than serum creatinine. Nephron 92(1):224-226
29. Schnabel RB, Schulz A, Messow CM, Lubos E, Wild PS, Zeller T, Sinning CR, Rupprecht HJ, Bickel C, Peetz D, Cambien F, Kempf T, Wollert KC, Benjamin EJ, Lackner KJ, Münzel TF, Tiret L, Vasan RS, Blankenberg S (2010) Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J 31(24):3024-3031. doi: 10.1093/eurheartj/ehq322
30. Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin c with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease. Circulation 115(2):173-179. doi: 10.1161/circulationaha.106.644286
31. Windhausen F, Hirsch A, Fischer J, van der Zee PM, Sanders GT, van Straalen JP, Cornel JH, Tijssen JGP, Verheugt FWA, de Winter RJ, Investigators ftIvCTiUCS (2009) Cystatin C for enhancement of risk stratification in non-ST elevation acute coronary syndrome patients with an increased troponin T. Clin Chem 55(6):1118-1125. doi: 10.1373/clinchem.2008.119669
32. Åkerblom A, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK (2012) Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the platelet inhibition and patient outcomes study. Clin Chem 58(1):190-199. doi: 10.1373/clinchem.2011. 171520
33. Silva D, Cortez-Dias N, Jorge C, Marques JS, Carrilho-Ferreira P, Magalhaes A, Martins SR, Goncalves S, da Silva PC, Fiuza M, Diogo AN, Pinto FJ (2012) Cystatin C as prognostic biomarker in ST-segment elevation acute myocardial infarction. Am J cardiol 109(10):1431-1438. doi: 10.1016/j.amjcard. 2012.01.356
34. Fox KA, Antman EM, Montalescot G, Agewall S, SomaRaju B, Verheugt FW, Lopez-Sendon J, Hod H, Murphy SA, Braunwald E (2007) The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 49(23):2249-2255
35. Liani M, Salvati F, Golato M, Tresca E (1996) Platelet glycoproteins GPIb and GPIIb/IIIa abnormalities in uremia. Nephron 72(4):716
36. Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S, Blais N, Lalonde L (2005) Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116(1):41-50. doi: 10.1016/j.thromres.2004.10.004
37. Darlington A, Ferreiro JL, Ueno M, Suzuki Y, Desai B, Capranzano P, Capodanno D, Tello-Montoliu A, Bass TA, Nahman NS, Angiolillo DJ (2011) Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 106(1):67-74. doi: 10.1160/th10-12-0785
38. Berger PB, Best PJM, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ (2005) The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the Do Tirofiban and ReoPro give similar efficacy outcome (TARGET) trial. Am Heart J 149(5):869-875. doi: 10.1016/j.ahj.2004.12.002
39. Sreedhara R, Itagaki I, Hakim RM (1996) Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 27(3):355-364